TubeMogul to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- TubeMogul, Inc. (NASDAQ: TUBE), a leading enterprise software company for brand advertising, today announced that members of the management team will present to the investment community at the following investor conferences:

RBC Capital Markets' Technology, Internet, Media and Telecommunications Conference Date: Wednesday, November 11, 2015 Time: 4:00 p.m. ET Location: Westin Times Square, New York, NY

UBS Global Technology Conference Date: Monday, November 16, 2015 Time: 3:30 p.m. PT Location: Ritz-Carlton Hotel, San Francisco, CA

Jefferies Austin Internet & Software Summit Date: Wednesday, November 18, 2015 Time: 1:20 p.m. CT Location: W Austin Hotel, Austin, TX

A live webcast for each presentation will be accessible on the investor relations section of the TubeMogul website (http://investor.tubemogul.com). An archived replay of each webcast will be available following the live presentations.

About TubeMogul

TubeMogul (NASDAQ: TUBE) is an enterprise software company for brand advertising. By reducing complexity, improving transparency and leveraging real-time data, our platform enables advertisers to gain greater control of their global advertising spend and achieve their brand advertising objectives. TubeMogul was incorporated in 2007 and is based in Emeryville, California with operations in Kyiv, London, Mexico City, New York, Paris, Sao Paulo, Shanghai, Singapore, Sydney, Tokyo, Toronto, Washington D.C. and offices across the United States.

TubeMogul and the TubeMogul logo are trademarks or registered trademarks of TubeMogul, Inc. in the United States and other countries.

CONTACT: Media Contact:
         David Burch
         [email protected]

         Investor Relations Contact:
         Alex Wellins
         The Blueshirt Group
         [email protected]

You May Also Be Interested In

• Jersey Mike's launches IPO roadshow, targets NYSE listing as JMKE
• Vaisala Corporation Half Year Financial Report January–June 2026: Strong growth in orders received driven by record-high demand in Industrial Measurements
• OMEICOS’ OMT-28 Headed for Phase 3 in Primary Mitochondrial Diseases (PMD) Following Positive End-of-Phase 2 Meeting with the FDA